Brooklyn, NY, Sept. 07, 2016 -- The ability of umbilical cord stem cells to overcome many of the shortcomings and complications associated with blood transfusion has helped in the creation of a global, multibillion dollar umbilical cord stem cells market. A new report that is now available on QYResearchReports.com studies in detail the factors that will encourage the growth of the global umbilical cord stem cells market and provides specific recommendations for growth. The report is titled, ‘Global Umbilical Cord Stem Cells Market Research Report 2021.’
Get Sample Copy of Report for more Professional and Technical insights : http://www.qyresearchreports.com/sample/sample.php?rep_id=787396&type=E
Although cord blood came into the spotlight in the late 1980s for proving useful in treating blood diseases in children, its real commercial potential was only realized several years later when it was observed that several disorders among adults could also be treated using cord blood. With the outcomes of adult umbilical cord blood transplantation having dramatically improved over the last decade, there is now a growing popular acceptance for it. This has resulted in an unprecedented number of public and private cord blood banks coming up, further driving the growth of the global umbilical cord stem cells market.
Despite a positive long-term outlook for the global umbilical cord stem cells market, there are a few challenges that may slow down the growth of the market. The greatest limitation currently is that blood from a single umbilical cord for the purpose of cord blood transplantation contains fewer haematopoeitic stem cells than what would be obtained via bone marrow donation. A common technique to counter this drawback is to obtain blood from two umbilical cords – a concept known as double cord blood transplant. Although this technique has shown encouraging results in clinical trials, it continues to limit the scope of umbilical cord stem cells in treating adults in the short term.
A key opportunity in the global umbilical cord stem cells market is the increasing clinical evidence coming to the fore about umbilical cord stem cells being useful in treating more than just blood diseases. For instance, reports suggesting the ability of umbilical cord stem cells to repair cardiovascular tissues could lead to a major breakthrough in the coming years. However, these possibilities will remain limited to research facilities until scientists can find ways to reproduce the desired results in different patients.
The leading companies that have established a firm standing in the global umbilical cord stem cells market have been profiled and analyzed in the report. These companies include NeuroNova AB, Neuralstem, NeuroGeneration, ReNeuron Limited, StemCells, Asterias Biotherapeutics, STEMCELL Technologies, Thermo Fisher Scientific, Axol Bio, and Lonza.
Interested in report: Please follow the below link to meet your Requirements http://www.qyresearchreports.com/report/global-umbilical-cord-stem-cells-market-research-report-2021.htm
This report studies the global umbilical cord stem cells market in North America, Europe, Southeast Asia, China, India, and Japan. The market is studied based on the following product types: Type I, type II, and type III. The key application areas studied include: hospitals, medical care, and laboratories.
Trending Reports:
- Global Epithelial Stem Cells (ESCs) Market Report 2016
- Global Fetal Stem Cells Sales Market Report 2021
- Global Cord Blood Stem Cells Sales Market Report 2021
For Latest Market Research News Visit @ http://www.qyresearchreports.com/qyresearch-news.htm
About Us
QYResearchReports.com is the trusted source of market research reports among clients that include prestigious Chinese companies, multinational companies, SMEs, and private equity firms. Our market research reports focus on categories including but not limited to: Chemicals, Energy, Alternative and Green Energy, Machinery, Manufacturing, Glass, Pharmaceuticals and Materials READ MORE
QYResearchReports 1820 Avenue M Suite #1047 Brooklyn, NY 11230 United States Toll Free: 866-997-4948 (USA-CANADA) Tel: +1-518-621-2074 Email: [email protected] Website: http://www.qyresearchreports.com


DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Washington Post Publisher Will Lewis Steps Down After Layoffs
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Anta Sports Expands Global Footprint With Strategic Puma Stake
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



